Why Buy Domino’s Pizza Stock?
When you think of growth stocks, you probably imagine technology…
Sell
37
ACRV Quote, Financials, Valuation and Earnings
Last price:
$6.60
Seasonality move
:
28.76%
Day range:
$5.75 - $6.70
52-week range:
$3.19 - $11.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.05x
Volume:
70K
Avg. volume:
56.4K
1-year change:
32.93%
Market cap:
$206.1M
Revenue:
--
EPS (TTM):
-$2.71
Analysts' Opinion
-
Consensus RatingAcrivon Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.13, Acrivon Therapeutics has an estimated upside of 218.9% from its current price of $6.62.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.00 representing 100% downside risk from its current price of $6.62.
Fair Value
-
According to the consensus of 5 analysts, Acrivon Therapeutics has 218.9% upside to fair value with a price target of $22.13 per share.
ACRV vs. S&P 500
-
Over the past 5 trading days, Acrivon Therapeutics has overperformed the S&P 500 by 7.46% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Acrivon Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Acrivon Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Acrivon Therapeutics reported revenues of --.
Earnings Growth
-
Acrivon Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Acrivon Therapeutics reported earnings per share of -$0.59.
Enterprise value:
18.7M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.29x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$27M | -$56M | -$85.3M | -$16.1M | -$25.1M | |
| EBITDA | -$26.7M | -$55.5M | -$84.4M | -$16M | -$24.9M | |
| Diluted EPS | -$1.84 | -$2.67 | -$2.71 | -$0.66 | -$0.59 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $78.7M | $144.5M | $189M | |
| Total Assets | -- | -- | $87.7M | $151.1M | $214.7M | |
| Current Liabilities | -- | -- | $6.4M | $9.3M | $14.8M | |
| Total Liabilities | -- | -- | $133.3M | $12.9M | $17.8M | |
| Total Equity | -- | -- | -$45.6M | $138.1M | $196.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$39.6M | -$60.7M | -$9.8M | -$17.3M | |
| Cash From Investing | -- | -$64.9M | -$45.6M | $1.5M | $16M | |
| Cash From Financing | -- | $102.3M | $119.7M | $78K | -$1.5M | |
| Free Cash Flow | -- | -$40M | -$63.8M | -$9.8M | -$18.3M | |
ACRV
Sector
Market Cap
$206.1M
$49.2M
Price % of 52-Week High
55.63%
48.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
32.93%
-30.94%
Beta (5-Year)
--
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$6.06
200-day SMA
Sell
Level
$7.67
Bollinger Bands (100)
Sell
Level
6.64 - 8.5
Chaikin Money Flow
Sell
Level
-22.1M
20-day SMA
Buy
Level
$6.54
Relative Strength Index (RSI14)
Sell
Level
49.99
ADX Line
Buy
Level
13.46
Williams %R
Neutral
Level
-41.0628
50-day SMA
Sell
Level
$7.19
MACD (12, 26)
Sell
Level
-0.32
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
37.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Stock Forecast FAQ
In the current month, ACRV has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ACRV average analyst price target in the past 3 months is $22.13.
-
Where Will Acrivon Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Acrivon Therapeutics share price will rise to $22.13 per share over the next 12 months.
-
What Do Analysts Say About Acrivon Therapeutics?
Analysts are divided on their view about Acrivon Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Acrivon Therapeutics is a Sell and believe this share price will drop from its current level to $17.00.
-
What Is Acrivon Therapeutics's Price Target?
The price target for Acrivon Therapeutics over the next 1-year time period is forecast to be $22.13 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ACRV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Acrivon Therapeutics is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ACRV?
You can purchase shares of Acrivon Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Acrivon Therapeutics shares.
-
What Is The Acrivon Therapeutics Share Price Today?
Acrivon Therapeutics was last trading at $6.60 per share. This represents the most recent stock quote for Acrivon Therapeutics. Yesterday, Acrivon Therapeutics closed at $6.62 per share.
-
How To Buy Acrivon Therapeutics Stock Online?
In order to purchase Acrivon Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Companies Are In The VanEck Semiconductor ETF?
There’s a lot to love about the VanEck Semiconductor ETF,…
How High Can Palantir Stock Go?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
